LO OVRAL SUMMARY
21 white LO/OVRAL tablets, each containing 0.3 mg of norgestrel ( dl
-13-beta-ethyl-17-alpha-ethinyl-17-beta-hydroxygon-4-en-3-one), a totally synthetic progestogen, and 0.03 mg of ethinyl estradiol (19-nor-17(alpha)-pregna-1,3,5 (10)-trien-20-yne-3,17-diol), and 7 pink inert tablets.
Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
Media Articles Related to LO Ovral (Norgestrel / Ethinyl Estradiol)
Does hormonal contraception alleviate premenstrual symptoms?
Source: Endocrinology News From Medical News Today [2016.11.29]
The results of a new study designed to compare the severity and timing of perimenstrual symptoms among women who do or do not use cyclic hormonal contraception are reported in Journal of Women's...
New Consensus on Hormonal Management in Women With Stroke
Source: Medscape Critical Care Headlines [2017.01.20]
A multidisciplinary expert panel provides evidence-based recommendations on the lifelong management of pregnancy, contraception, and hormone replacement in women with previous stroke.
Medscape Medical News
IUD vs. Pill: What Contraceptive Method is Best for Me?
Source: Sexual Health / STDs News From Medical News Today [2016.11.29]
What is the birth control pill and what is an IUD? Learn about things to consider when choosing between the two and other contraception options.
Published Studies Related to LO Ovral (Norgestrel / Ethinyl Estradiol)
A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. [2005.02]
OBJECTIVES: To evaluate the impact on lipid and carbohydrate variables of a combined one-third ethinyl estradiol (EE)/levonorgestrel (LNG) dose reduction in oral contraceptives... CONCLUSION: Similar effects on the lipid and carbohydrate profiles were found for both preparations. The balanced one-third EE dose reduction in this new oral contraceptive caused slightly lower, but insignificant, changes in the lipid and carbohydrate variables compared with the reference treatment.
Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. [2005.02]
BACKGROUND: This trial was conducted to compare cycle control with vaginal ring a combined contraceptive vaginal ring, and a combined oral contraceptive (COC) delivering 30 mug ethinylestradiol (EE) and 150 mug levonorgestrel... CONCLUSIONS: Cycle control with vaginal ring was excellent and superior to that of a COC containing 30 mug EE.
A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. [2005.01]
This open-label randomized study compared the effects of two combined oral contraceptives (OCs) containing 3 mg drospirenone (DRSP)/30 microg ethinyl estradiol (EE) with 150 microg levonorgestrel (LNG)/30 microg EE on the prevalence and changes from baseline of premenstrual symptoms after six cycles...
Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. [2004.11]
We evaluated ovarian follicular development in women during compliant use of oral contraceptives (OC). Thirty-six healthy women received: [35 microg ethinyl estradiol (21)/180 microg norgestimate (7), 215 microg norgestimate (7), 250 microg norgestimate (7)]; [30 microg ethinyl estradiol (21)/150 microg desogestrel (21)]; or [20 microg ethinyl estradiol (21)/100 microg levonorgestrel (21)] for 3 consecutive 28-day cycles...
Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. [2004.06]
OBJECTIVES: Poor cycle control and tolerability can be reasons for irregular pill intake. This study compared the tolerability of two low-dose oral contraceptives and their effect on cycle control... CONCLUSIONS: 20EE/DSG provided better cycle control than 20EE/LNG with less treatment discontinuation due to unacceptable bleeding. There were no apparent differences between the two groups regarding tolerability and quality of life. There was less acne with 20EE/DSG. Copyright 2004 Elsevier Inc.
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, LO Ovral has an overall score of 9. The effectiveness score is 10 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
LO Ovral review by 3 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || acne and contraception|
|Dosage & duration:|| || standard 30 mcg (dosage frequency: every day) for the period of 8 years|
|Other conditions:|| || hirsutism|
|Other drugs taken:|| || spironolactone|
|Benefits:|| || Within days, the acne disappeared. When taken continuously for 3-5 months at a time, the acne never reappeared and the hirsutism decreased substantially. We then added laser hair removal and stopped the spironolactone.|
|Side effects:|| || Spironolactone caused occasional leg cramping. The Lo-ovral caused some water retention.|
|Comments:|| || Spironolactone was taken 50 mg a day and then increased after 3 months to 100 mg twice a day. The Lo-ovral was taken each day. The laser hair removal was every 6 weeks. The acne was completely under control. When the OCP was stopped, the acne returned.|
Page last updated: 2017-01-20